Biotech & Life Sciences
Hemostemix Secures Full LARTA Approval for Its VesCell Study in The Bahamas
C$0.05 a unit. That is the price Hemostemix set for new investors on October 7, in the same release that announced full approval to run its lead cell therapy study in The Bahamas. Further down that release, the company disclosed that a manufacturing license deal it first announced in February 2025 will not go ahead.…
Vaxcyte’s VAX-31 Meets Phase 3 Endpoints, Then Launches $1 Billion Raise
Alector’s stock ended Friday at $1.81, down 42.7% over the past year. Monday morning, Genentech put $100 million upfront on a Parkinson’s program that has not yet entered the clinic. Vaxcyte had the busier day: Phase 3 data before the open, a $1 billion financing after the close. Alector Licenses AL050 to Genentech for $100…
Marvel Biosciences Closes $1.6 Million Raise to Fund MB-204 Phase 1 Deposit
Marvel Biosciences priced its units at 15 cents and asked investors for up to $3 million. It closed with $1.6 million, after a first closing originally expected around August 14 slid to the end of September. The money pays the deposit on a trial the company once expected to begin in the second quarter. Marvel…
Lifecore Biomedical Agrees to Webster Buyout Worth Up to $9.67 a Share
Alcon has signed up to help finance the purchase of one of its own suppliers. Whether Lifecore Biomedical shareholders end up with $6.28 a share or as much as $9.67 depends partly on how much Alcon keeps ordering. Kodiak Sciences had the louder Monday. Filana Therapeutics got a clinical hold lifted and watched the rally…
TempraMed Posts Record July Sales, Then Announces a CenterWell Pharmacy Deal
The contract is dated August 25. TempraMed announced it on September 23, in a release whose news section runs a single sentence. The company on the other side of that sentence is CenterWell Pharmacy, the pharmacy services brand of Humana. CenterWell Pharmacy Agreement Dated August 25, Announced September 23 TempraMed Technologies Ltd. (CSE: VIVI) (OTCQB:…
Longeveron’s HLHS Trial Misses Primary Endpoint, Reviews Options
A trial run in China just handed Cue Biopharma a stock chart that spiked more than 40% before giving almost all of it back in the same session. Longeveron’s pediatric heart trial met the opposite fate, missing its main goal just days after the company finally cleared a Nasdaq compliance deadline it had spent a…
Inside NurExone’s Push Into Eye and Skin Applications for Its Exosome Platform
NurExone’s exosomes are good at finding damaged tissue. Getting them past the skin’s outer barrier without breaking apart along the way is a separate problem entirely. This week the company partnered with an Israeli device maker that already has an FDA-cleared answer to exactly that problem, the same week its shareholders quietly handed the board…
Tenon Medical Surges on Debt Repayment, Negative Equity Remains
A $5 million debt payment doubled Tenon Medical’s stock price in two days. The company had negative equity going into that payment. AEON Biopharma spent the same stretch adding another data point to a multi-year case that its botulinum toxin candidate matches BOTOX at the molecular level. Neither story ends with an approved product yet,…
Apptly’s OTCQB Listing Follows a Fresh FDA-Approved Imaging Partnership
Apptly Health Technologies signed a partnership with the maker of the only FDA-approved breast CT system on Tuesday. Two days later, on Wednesday, the company’s stock became tradable to a much larger pool of US investors for the first time. The timing wasn’t a coincidence so much as a pattern; it’s roughly the pace the…
Biotech Sector Snapshot: Trial Failure Meets a Rally
One failed trial erased more than a billion dollars from a single biotech’s market value this week. The sector it trades in barely noticed. Both of those facts are true at the same time, and untangling why is more useful than picking a single winner to write about. The Rally’s Math: XBI Up 36% Even…
